Aequus Pharmaceuticals Reports Revenue Growth Amid Restructuring
Company Announcements

Aequus Pharmaceuticals Reports Revenue Growth Amid Restructuring

Story Highlights

Aequus Pharmaceuticals (TSE:AQS) has released an update.

Aequus Pharmaceuticals reports a 77.50% increase in revenue for Q3 2024 compared to the previous year, driven by the continued growth of their product Zimed® PF. The company has restructured to reduce costs amidst delayed profitability, while also exploring strategic alternatives to enhance future performance.

For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Reports Strong Q2 Financials
TipRanks Canadian Auto-Generated NewsdeskAequus Pharmaceuticals Celebrates Zimed® PF Sales Record
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App